CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an announcement.
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, has released its unaudited financial results for the first quarter of 2025, showing a decrease in revenue and net profit compared to the previous year. Despite the decline in financial performance, the company managed to improve its net cash flow from operating activities significantly, indicating potential operational adjustments or efficiencies.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a company in the pharmaceutical industry, focusing on the development and production of innovative drugs. It operates through its subsidiary, CSPC Innovation Pharmaceutical Co., Ltd., which is listed on the ChiNext of Shenzhen Stock Exchange.
YTD Price Performance: 8.47%
Average Trading Volume: 29,601
Technical Sentiment Signal: Buy
Current Market Cap: $8.99B
For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.